title: Dendritic cell engineering for tumor immunotherapy: from biology to clinical translation.
abstract: Dendritic cells (DCs) are the most potent APCs, with the ability to orchestrate a repertoire of immune responses. DCs play a pivotal role in the initiation, programming and regulation of tumor-specific immune responses, as they are poised to take up, process and present tumor antigens to naive or effector T lymphocytes. Although, to an extent, DC-based immunotherapeutic strategies have successfully induced specific anti-tumor responses in animal models, their clinical efficacy has rarely been translated into the clinic. This article attempts to present a complete picture of recent developments of DC-based therapeutic strategies addressing multiple components of tumor immunoenvironment. It also showcases certain practical intricacies in order to explore novel strategies for providing new impetus to DC-based cancer vaccination.
authors.affiliation: Division of Translational Research, Tata Memorial Centre, ACTREC, India.
authors.forename: Arpit
authors.initials: A
authors.lastname: Bhargava
authors.forename: Dinesh
authors.initials: D
authors.lastname: Mishra
authors.forename: Smita
authors.initials: S
authors.lastname: Banerjee
authors.forename: Pradyumna Kumar
authors.initials: PK
authors.lastname: Mishra
mesh_terms: D000818:Animals; D017951:Antigen Presentation; D000951:Antigens, Neoplasm / Q000276:immunology; D019496:Cancer Vaccines; D060846:Cell Engineering; D003713:Dendritic Cells / Q000276:immunology* / Q000637:transplantation*; D004195:Disease Models, Animal; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008213:Lymphocyte Activation; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D013601:T-Lymphocytes / Q000276:immunology*; D057170:Translational Research, Biomedical; D059016:Tumor Microenvironment
chemical_list: D000951:Antigens, Neoplasm; D019496:Cancer Vaccines